Feb 16, 2024 / 03:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q3 FY24 earnings conference call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Utkarsh Gandhi - Glenmark Pharmaceuticals Ltd - General Manager, Investor Relations
Thank you, Lizanne. Good morning, everyone. Welcome to the Q3 FY24 results conference call of Glenmark Pharmaceuticals Limited. Before we start the Q&A, we'll review the overall performance of the company for the third quarter of FY24.
For third quarter of FY24, Glenmark's consolidated revenue from operations was at INR29,096 million as against INR34,639 million in the corresponding quarter last year, recording a YoY decline of 16%. The lower sales in the current quarter was mainly on account of a one-time impact on the company's India business.
And excluding this impact, the approximate growth over previous year
Q3 2024 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Feb 16, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers